Showing results (101-110 of 126) with videos related to
Sort By:
Pageof 13
Journal of the National Cancer Institute|March 31, 2010
Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitorsMichael L Maitland, George L Bakris, Henry R Black, et al.Investigational New Drugs|December 16, 2015
A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancerDustin A Deming, Ludmila L Cavalcante, Sam J Lubner, et al.European Urology Oncology|August 19, 2020
Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED TrialAlan H Bryce, Yu Hui Chen, Glenn Liu, et al.Investigational New Drugs|October 17, 2014
A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumorsNoelle K LoConte, Albiruni R A Razak, Percy Ivy, et al.European Urology|May 11, 2016
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer CohortMatthew R Smith, Emmanuel S Antonarakis, Charles J Ryan, et al.The Oncologist|June 2, 2019
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate CancerElisabeth Heath, Lance Heilbrun, Heather Mannuel, et al.Prostate Cancer and Prostatic Diseases|November 11, 2018
Quantification of bone flare on 18F-NaF PET/CT in metastatic castration-resistant prostate cancerAmy J Weisman, Stephanie A Harmon, Timothy G Perk, et al.Cancer Medicine|April 9, 2022
A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782)Ticiana A Leal, Marina N Sharifi, Nancy Chan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2017
Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without DocetaxelLauren C Harshman, Yu-Hui Chen, Glenn Liu, et al.The New England Journal of Medicine|August 6, 2015
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerChristopher J Sweeney, Yu-Hui Chen, Michael Carducci, et al.Pageof 13